|
Match
|
Document |
Document Title |
|
|
8142781 |
Fusion proteins for blood-brain barrier delivery
The invention provides compositions, methods, and kits for increasing transport of agents across the blood brain barrier while allowing their activity once across the barrier to remain...
|
|
|
8138141 |
HMG1 antibody for treating inflammatory conditions
There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount...
|
|
|
8138154 |
Biglycan and related therapeutics and methods of use
The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with...
|
|
|
8080246 |
Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules
The present invention relates to specific CSF1R ECD fusion molecules that exhibit improved therapeutic properties. The invention also relates to polypeptide and polynucleotide sequences, vectors,...
|
|
|
8034777 |
Modified anticholinergic neurotoxins as modulators of the autoimmune reaction
The invention comprises a composition of matter and method of its use for the treatment of multiple sclerosis in humans. The composition is a modified anticholinergic alpha-neurotoxin....
|
|
|
7973011 |
Blockade of gamma-secretase activity to promote myelination by oligodendrocytes
Methods are provided for enhancing myelination. Myelination is enhanced by administration of agents that are inhibitors of γ-secretase. Methods of screening for pharmaceutically active compounds ...
|
|
|
7968516 |
Treatment of multiple sclerosis and other autoimmune diseases by use of calpin inhibitors
Described herein are compounds and methods for treating or preventing a neurologic, otologic, or ophthalmologic disease in a subject. Also described herein are compounds that can be used as...
|
|
|
7964563 |
Oligodendrocyte precursor cell proliferation regulated by prolactin
The present invention relates to a method to increase oligodendrocytes and oligodendrocyte precursor cells through administration of prolactin or a prolactin inducing agent.
|
|
|
7951371 |
Soluble lymphotoxin-β receptor fusion protein and methods for inhibiting lymphotoxin β-receptor signaling
This invention relates to compositions and methods comprising “lymphotoxin-β-receptor blocking agents”, which block lymphotoxin-β receptor signalling. Lymphotoxin-β receptor blocking agents are us...
|
|
|
7855176 |
Reduced volume formulation of glatiramer acetate and methods of administration
A method for reducing frequency of relapses in a human patient afflicted with relapsing-remitting multiple sclerosis (RRMS) comprising administering to the patient 0.5 ml of an aqueous...
|
|
|
7825093 |
Methods of using OSK1 peptide analogs
Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition...
|
|
|
7807645 |
Method of treating degenerative disorders of the nervous system by administration of fibrinogen fragment
The invention herein related to methods and compositions for treating nervous system disorders. The methods comprise peptides that bind to receptors important in disease progression, thus...
|
|
|
7781405 |
Methods for reducing oxidative damage
The invention provides a method for reducing oxidative damage in a mammal, a removed organ, or a cell in need thereof. The method comprises administering an effective amount of an aromatic cationic...
|
|
|
7745404 |
Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis
Methods for treating and preventing multiple sclerosis by administering to a patient an effective amount of calcitonin, calcitonin-like peptides or calcitonin mimetics to a patient. Additionally,...
|
|
|
7732407 |
Method for treatment of demyelinating central nervous system disease
A method for treating demyelinating central nervous system diseases in a subject that comprises administering to the subject a composition comprising a therapeutically active amount of colony...
|
|
|
7723303 |
Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
This invention provides novel active agents (e.g. peptides, small organic molecules, amino acid pairs, etc.) peptides that ameliorate one or more symptoms of atherosclerosis and/or other...
|
|
|
7723290 |
Compositions and methods for modulating the immune system
A novel class of embryo derived peptides are described (Preimplantation factor) that were generated synthetically and were tested on peripheral blood immune cells and shown to block activated but...
|
|
|
7700561 |
Abuse-resistant amphetamine prodrugs
The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for...
|
|
|
7700105 |
Methods of inducing IL-10 production
The invention provides a method of inducing IL-10 production.
|
|
|
7696154 |
Methods for treating interleukin-18 mediated disorders with interleukin-18 binding proteins
Interleukin-18 binding proteins which are capable of binding IL-18 and of modulating and/or blocking IL-18 activity are provided. Methods for the isolation and recombinant production, DNAs encoding...
|
|
|
7691809 |
Lactoferrin for age related disorders in humans
The method of the present invention provides a novel use of lactoferrin to modulate the molecular events during development of age-related disorders in humans. More specifically, the present...
|
|
|
7683032 |
Deglycosylated and desialidated long pentraxin PTX3
Deglycosylated long pentraxin PTX3 and desialidated long pentraxin PTX3 are disclosed, as well as processes for their preparation, pharmacological compositions containing them, and their use for...
|
|
|
7659243 |
Treatment of ALS and variants thereof consisting of primary lateral sclerosis (PLS) or spinal muscular atrophy (SMA)
The invention relates to the use of angiogenin, or a fragment or variant thereof, to treat diseases or conditions characterised by neuronal injury or death, or axonal degeneration, especially...
|
|
|
7655221 |
Methods of treating disease with random copolymers
The invention relates to novel methods and kits for treating or preventing disease through the administration of random copolymers comprising amino acids tyrosine (Y), phenylalanine (F), alanine...
|
|
|
7655222 |
Method of using interferon-like protein ZCYTO20 (IL-28A) or ZCYTO22 (IL-28B) to treat hepatitis C
The present invention relates to polynucleotide and polypeptide molecules for zcyto20, zcyto21, zcyto22, zycto24, and zcyto25 proteins which are most closely related to interferon-α at the amino ...
|
|
|
7629313 |
Immunomodulatory polymeric antigens for treating inflammatory pathologies
Provided are natural and synthetic immunomodulatory polymeric antigens (SPAs), compositions containing SPAs, and methods of using these natural and synthetic SPAs and compositions to prevent or...
|
|
|
7605132 |
Protective factors against inflammation, burns and noxious stimuli
Peptide factors isolated from skin following exposure to chemical or thermal injury and treatment with iodine preparations are capable of reducing or ameliorating the extent of injury when...
|
|
|
7601368 |
Purified Arabinogalactan-Protein (AGP) composition useful in the treatment psoriasis and other disorders
A purified Arabinogalactan-Protein (AGP) composition isolated through a selective method from the leaves and/or stems of Argemone mexicana plant is described. Also described is a purified...
|
|
|
7589066 |
Potent and specific immunoproteasome inhibitors
Compounds and methods of selectively inhibiting an immunoproteasome are described. Also described are methods of treating a cancer, an inflammation, and/or an autoimmune disease and methods of...
|
|
|
7585507 |
Nucleic acid molecules and polypeptides for immune modulation
The invention provides gp38 polypeptides, which play a role in immunomodulation, nucleic acid molecules encoding these polypeptides, and therapeutic and diagnostic methods employing these...
|
|
|
7566696 |
Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis
Methods for treating and preventing multiple sclerosis by administering to a patient an effective amount of calcitonin, calcitonin-like peptides or calcitonin mimetics to a patient. Additionally,...
|
|
|
7553811 |
Methods and compositions for modulating immunity
Methods and compositions for inducing immune suppression are disclosed. The methods involve administering an effective amount of a CD200 protein or a nucleic acid encoding a CD200 protein. The...
|
|
|
7550263 |
Method for the production of fusion proteins in transgenic mammal milk
Desirable fusion proteins can be produced in and purified from the milk of transgenic animals. The peptides are made as fusion proteins with a suitable fusion partner such as human...
|
|
|
7550439 |
Methods for reducing oxidative damage
The invention provides a method for reducing oxidative damage in a mammal, a removed organ, or a cell in need thereof. The method comprises administering an effective amount of an aromatic cationic...
|
|
|
7531516 |
Peptidic compounds selectively binding to P-selectin
The present invention relates to compounds which bind selectively to the adhesion molecule human P-selectin, and particularly to such compounds comprising a peptide with an amino acid sequence...
|
|
|
7531504 |
Pharmaceutical composition and method for inhibiting gastrointestinal inflammation
Peptide antagonists of zonulin are disclosed, as well as methods for the use of the same. The peptide antagonists bind to the zonula occludens receptor, yet do not physiologically modulate the...
|
|
|
7511013 |
Cyclosporin analogues and their pharmaceutical uses
The compounds of the present invention are represented by Formula I, as shown below: or a pharmaceutically acceptable salt thereof, with X, R0, R1, and R2 defined herein.
|
|
|
7491705 |
Alpha-ketoamide derivative, and production method and use thereof
The present invention provides a compound represented by the formula (I): (wherein R1 is a lower alkyl substituted by a lower alkoxy or a heterocyclic group, or a heterocyclic group;R2 is a lower...
|
|
|
7485626 |
Combinations of enzyme inhibitor-containing preparations and the use thereof
The invention comprises a process wherein the DNA synthesis and, thus, the proliferation of mononuclear cells (MNZ) and of T cells as well is inhibited by the simultaneous and combined inhibition...
|
|
|
7473679 |
Treatments employing neuronal exocytosis-inhibiting peptides
The peptide has a sequence of 3 to 30 adjacent amino acids from the amino end of protein SNAP-25 and is useful as neuronal exocytosis inhibitor. The cosmetic and pharmaceutical compositions contain...
|
|
|
7445772 |
Heterodimeric four helix bundle cytokines
Heterodimeric proteins comprising two helical bundle cytokines are disclosed. One of the polypeptides comprises zsig81 and a second polypeptide which comprises either p19 (aka IL-12A) or p35 (aka...
|
|
|
7439231 |
Inhibitors of antigen presentation by MHC class II molecules and methods of use thereof
The present invention relates to compounds, pharmaceutical compositions containing such compounds and methods for their use. In particular, the compounds of the invention are useful for the...
|
|
|
7429384 |
Chimeric antagonist anth1
A recombinant chimeric antagonist formed by a 60 amino acid fragment of the N-terminal region of human interleukin 2 (IL-2) fused to the N-terminal of the extracellular region of the alpha subunit...
|
|
|
7429560 |
Ketoamide inhibitors in chronic nerve disease
Compositions and methods for treating neural pathologies are provided. In particular, compositions and methods for treating neural pathologies including axonal degeneration are provided. The...
|
|
|
7425332 |
Treatment of autoimmune conditions with Copolymer 1 and related Copolymers
The present invention is directed to polypeptides containing at least three amino acids randomly joined in a linear array; wherein at least one of the three amino acids is an aromatic amino acid,...
|
|
|
7425532 |
Use of alanyl aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors
The present invention relates to the use of one inhibitor or of several inhibitors of alanyl aminopeptidases and/or of enzymes having a similar substrate specificity for the induction of the...
|
|
|
7402563 |
EPF derived peptides and therapeutic compositions
The present invention provides assays for the study of the interaction of EPF and its EPF-related peptides with a hDRR receptor. The assays are useful to identify whether a test compound can bind...
|
|
|
7393830 |
Prolactin induced increase in neural stem cell numbers
The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using prolactin. The method can be practiced in vivo to obtain more neural stem cells in situ,...
|
|
|
7368421 |
Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
The present invention provides a new use of DP IV-inhibitors. The compounds of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, are useful in...
|
|
|
7368429 |
Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
Human myelin basic protein (h-MBP) has a molecular weight of 18.5 KD and contains 170 amino acid residues. Synthetic peptides ranging in length from about 8 to 25 residues and covering the entire...
|